167. Marfan syndrome Clinical trials / Disease details
Clinical trials : 20 / Drugs : 39 - (DrugBank : 10) / Drug target genes : 10 - Drug target pathways : 50
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-000749-13-GB (EUCTR) | 30/07/2005 | 20/06/2005 | A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. | A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. | Marfan Syndrome | Trade Name: Atenolol Product Name: Atenolol Product Code: N/A INN or Proposed INN: N/A Other descriptive name: N/A Trade Name: Coversyl Product Name: Coversyl Product Code: N/A INN or Proposed INN: N/A Other descriptive name: PERINDOPRIL Trade Name: Verapamil Product Name: Verapamil SR Product Code: N/A INN or Proposed INN: N/A Other descriptive name: N/A | Cardiff University | NULL | Not Recruiting | Female: yes Male: yes | 60 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom | ||
| 2 | NCT00485368 (ClinicalTrials.gov) | January 2004 | 11/6/2007 | Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome | The Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome. | Marfan Syndrome | Drug: Coversyl (perindopril) | Bayside Health | Baker Heart Research Institute;The Alfred | Completed | 18 Years | 40 Years | Both | 17 | Phase 3 | NULL |